The Board of Trustees of the Leland Stanford Junior University
发明人:
LEEPER, Nicholas J.,WEISSMAN, Irving L.
申请号：
EP14845184
公开号：
EP3046627A4
申请日:
2014.09.15
申请国别(地区):
EP
年份:
2017
代理人:
摘要：
Smooth muscle cells (SMC) from subjects carrying at least one 9p21 risk factor, can be resistant to efferocytosis, leading to the retention of such cells in the necrotic core of atherosclerotic plaque. In the methods of the invention, an agent that increases efferocytosis of cellular components of coronary plaque, including efferocytosis of apoptotic smooth muscle cells, is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce atherosclerotic plaque in the individual.
